Lycera Corp.: Series A $36M

Posted in I - Series A, Q - 2Q09, R - MID WEST, X - IBD, X - Lupus, X - RA, X - Therapeutic Platform, XX - MI

Lycera Corp (Ann Arbor, MA) a preclinical-stage biopharma company focused on small molecule immunomodulators for the treatment of rheumatoid arthritis, lupus erythematosis and inflammatory bowel disease, closed a $36M Series A financing. Participants include InterWest Partners, ARCH Venture Partners, Clarus Ventures and EDF Ventures.

Dec

2008

AnaMar Medical, AB: Series B $9.3M

Posted in I - Series B, Q - 4Q08, R - INTERNATIONAL, X - RA

AnaMar Medical (Sweden) preclinical-stage developer of small molecule suppressor of inflammation and cartilage destruction in rheumatoid arthritis, closed a $9.3M Series B financing. Participants include Koncentra Holding and LinkMed.

Dec

2008

Apitope International, Ltd.: Series A $12.8M

Posted in I - Series A, Q - 4Q08, R - INTERNATIONAL, X - Diagnostic, X - Multiple Sclerosis, X - RA, X - Vaccines

Apitope International (United Kingdome) developer of vaccines and diagnostics for autoimmune and allergic disease, closed a $12.8M Series A financing. Participants include Vesalius Biocapital, Vinnof and the University of Hasslet.

to top of page...